Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 1, 2015, Pages 89-100

  Fiorini, Claudia ^a   Cordani, Marco ^a   Padroni, Chiara ^a   Blandino, Giovanni ^b   Di Agostino, Silvia ^b   Donadelli, Massimo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Autophagy; Gain of function (GOF); Gemcitabine; Mutant p53; p53 reactivating molecules; Pancreatic adenocarcinoma

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 5,5' (2,5 FURANDIYL)BIS 2 THIOPHENEMETHANOL; ANTINEOPLASTIC AGENT; GEMCITABINE; MUTANT PROTEIN; PROTEIN P53; SERINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; PYRIMIDINE DERIVATIVE; TP53 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER RESISTANCE; CCNB1 GENE; CDK1 GENE; CELL NUCLEUS; CONTROLLED STUDY; DRUG POTENTIATION; GENE; GENE EXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MUTATION; PANCREATIC NEOPLASMS; PHOSPHORYLATION; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908632308     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.10.003     Document Type: Article

References (59)

1. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
2. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
3. Kleger A., Perkhofer L., Seufferlein T. Smarter drugs emerging in pancreatic cancer therapy. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO 2014, 25:1260-1270.
4. Moore P.S., Beghelli S., Zamboni G., Scarpa A. Genetic abnormalities in pancreatic cancer. Mol. Cancer 2003, 2:7.
5. Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6:909-923.
6. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
7. Muller P.A., Vousden K.H. p53 mutations in cancer. Nat. Cell Biol. 2013, 15:2-8.
8. Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Siegfried Z., Shiff I., Kogan I., Shay M., Kalo E., Blandino G., Simon I., Oren M., Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010, 17:273-285.
9. Strano S., Dell'Orso S., Di Agostino S., Fontemaggi G., Sacchi A., Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene 2007, 26:2212-2219.
10. Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V.G., Rotter V., Blandino G., Oren M. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 2007, 67:2396-2401.
11. Acin S., Li Z., Mejia O., Roop D.R., El-Naggar A.K., Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J. Pathol. 2011, 225:479-489.
12. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., El-Naggar A.K., Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
13. Morton J.P., Timpson P., Karim S.A., Ridgway R.A., Athineos D., Doyle B., Jamieson N.B., Oien K.A., Lowy A.M., Brunton V.G., Frame M.C., Evans T.R., Sansom O.J. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:246-251.
14. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
15. Bullock A.N., Fersht A.R. Rescuing the function of mutant p53. Nat. Rev. Cancer 2001, 1:68-76.
16. Donzelli S., Fontemaggi G., Fazi F., Di Agostino S., Padula F., Biagioni F., Muti P., Strano S., Blandino G. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2012, 19:1038-1048.
17. Lane D.P., Hupp T.R. Drug discovery and p53. Drug Discov. Today 2003, 8:347-355.
18. Masciarelli S., Fontemaggi G., Di Agostino S., Donzelli S., Carcarino E., Strano S., Blandino G. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 2014, 1601-1608.
19. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
20. Wiman K.G. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010, 29:4245-4252.
21. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002, 8:282-288.
22. Demma M.J., Wong S., Maxwell E., Dasmahapatra B. CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J. Biol. Chem. 2004, 279:45887-45896.
23. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286:2507-2510.
24. Roh J.L., Kang S.K., Minn I., Califano J.A., Sidransky D., Koch W.M. p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol. 2011, 47:8-15.
25. Xu J., Timares L., Heilpern C., Weng Z., Li C., Xu H., Pressey J.G., Elmets C.A., Kopelovich L., Athar M. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010, 70:6566-6576.
26. Fiorini C., Menegazzi M., Padroni C., Dando I., Dalla Pozza E., Gregorelli A., Costanzo C., Palmieri M., Donadelli M. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Apoptosis 2013, 18:337-346.
27. Di Agostino S., Strano S., Emiliozzi V., Zerbini V., Mottolese M., Sacchi A., Blandino G., Piaggio G. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006, 10:191-202.
28. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
29. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 1984, 22:27-55.
30. Osborn L., Kunkel S., Nabel G.J. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:2336-2340.
31. Imbriano C., Gurtner A., Cocchiarella F., Di Agostino S., Basile V., Gostissa M., Dobbelstein M., Del Sal G., Piaggio G., Mantovani R. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol. Cell. Biol. 2005, 25:3737-3751.
32. Manni I., Mazzaro G., Gurtner A., Mantovani R., Haugwitz U., Krause K., Engeland K., Sacchi A., Soddu S., Piaggio G. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J. Biol. Chem. 2001, 276:5570-5576.
33. Zhang G., Schetter A., He P., Funamizu N., Gaedcke J., Ghadimi B.M., Ried T., Hassan R., Yfantis H.G., Lee D.H., Lacy C., Maitra A., Hanna N., Alexander H.R., Hussain S.P. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One 2012, 7:e31507.
34. Burmakin M., Shi Y., Hedstrom E., Kogner P., Selivanova G. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2013, 19:5092-5103.
35. Li J., Merl M.Y., Chabot J., Saif M.W. Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going?. Highlights from the "2010 ASCO Annual Meeting" 2010, 11:310-312. (Chicago, IL, USA. June 4-8, 2010, Jop,).
36. Cecconi D., Palmieri M., Donadelli M. Proteomics in pancreatic cancer research. Proteomics 2011, 11:816-828.
37. Rufini A., Tucci P., Celardo I., Melino G. Senescence and aging: the critical roles of p53. Oncogene 2013, 32:5129-5143.
38. Aylon Y., Oren M. Living with p53, dying of p53. Cell 2007, 130:597-600.
39. Yoshida K., Miki Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci. 2010, 101:831-835.
40. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334.
41. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
42. Brown C.J., Cheok C.F., Verma C.S., Lane D.P. Reactivation of p53: from peptides to small molecules. Trends Pharmacol. Sci. 2011, 32:53-62.
43. Galmarini C.M., Clarke M.L., Falette N., Puisieux A., Mackey J.R., Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int. J. Cancer 2002, 97:439-445.
44. Camp E.R., Wang C., Little E.C., Watson P.M., Pirollo K.F., Rait A., Cole D.J., Chang E.H., Watson D.K. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013, 20:222-228.
45. Cascallo M., Calbo J., Capella G., Fillat C., Pastor-Anglada M., Mazo A. Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. Oncology 2005, 68:179-189.
46. Beghin A., Matera E.L., Brunet-Manquat S., Dumontet C. Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. Cell Cycle 2008, 7:3074-3082.
47. Hill R., Rabb M., Madureira P.A., Clements D., Gujar S.A., Waisman D.M., Giacomantonio C.A., Lee P.W. Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death Dis. 2013, 4:e791.
48. Unger T., Sionov R.V., Moallem E., Yee C.L., Howley P.M., Oren M., Haupt Y. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 1999, 18:3205-3212.
49. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-334.
50. Mizushima N. Physiological functions of autophagy. Curr. Top. Microbiol. Immunol. 2009, 335:71-84.
51. Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb. Perspect. Biol. 2010, 2:a001057.
52. Amelio I., Melino G., Knight R.A. Cell death pathology: cross-talk with autophagy and its clinical implications. Biochem. Biophys. Res. Commun. 2011, 414:277-281.
53. Dando I., Fiorini C., Pozza E.D., Padroni C., Costanzo C., Palmieri M., Donadelli M. UCP2 inhibition triggers ROS-dependent nuclear translocation of GAPDH and autophagic cell death in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta 2013, 1833:672-679.
54. Donadelli M., Dando I., Zaniboni T., Costanzo C., Dalla Pozza E., Scupoli M.T., Scarpa A., Zappavigna S., Marra M., Abbruzzese A., Bifulco M., Caraglia M., Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011, 2:e152.
55. Donohue E., Thomas A., Maurer N., Manisali I., Zeisser-Labouebe M., Zisman N., Anderson H.J., Ng S.S., Webb M., Bally M., Roberge M. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J. Cancer 2013, 4:585-596.
56. Yang S., Wang X., Contino G., Liesa M., Sahin E., Ying H., Bause A., Li Y., Stommel J.M., Dell'antonio G., Mautner J., Tonon G., Haigis M., Shirihai O.S., Doglioni C., Bardeesy N., Kimmelman A.C. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011, 25:717-729.
57. Fujii S., Mitsunaga S., Yamazaki M., Hasebe T., Ishii G., Kojima M., Kinoshita T., Ueno T., Esumi H., Ochiai A. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008, 99:1813-1819.
58. Yang A., Rajeshkumar N.V., Wang X., Yabuuchi S., Alexander B.M., Chu G.C., Von Hoff D.D., Maitra A., Kimmelman A.C. Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations. Cancer Discov. 2014, 4:905-913.
59. Rosenfeldt M.T., O'Prey J., Morton J.P., Nixon C., MacKay G., Mrowinska A., Au A., Rai T.S., Zheng L., Ridgway R., Adams P.D., Anderson K.I., Gottlieb E., Sansom O.J., Ryan K.M. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013, 504:296-300.